Clinical trial of comparison of intrathecal with intravenous Dexamethasone to reduce post operation complications after cesarean section

Clinical trial of comparison of intrathecal with intravenous Dexamethasone to reduce post operation complications after cesarean section due to intrathecal Morphine

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016112631095N1

Enrollment

120

Registered

2017-01-30

Start date

2016-10-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Single delivery by caesarean section. Delivery by elective caesarean section

Interventions

Intervention 1: The intervention group receives 0.2 mg of intrathecal Morphine plus 8 mg of intrathecal Dexamethasone made by Iran Hormone Co. injected in L3-L4 or L4-L5 space. Intervention 2: The co

Treatment - Drugs

Treatment - Other

The intervention group receives 0.2 mg of intrathecal Morphine plus 8 mg of intrathecal Dexamethasone made by Iran Hormone Co. injected in L3-L4 or L4-L5 space

The control group receives 0.2 mg of intrathecal Morphine in inter-vertebral space and 8 mg lntravenous Dexamethasone made by Iran Hormone Co. in addition to 2 cc intratechal distilled water in the sa

Eligibility

Sex/Gender

Female

Age

18 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria includes informed consent and undergoing elective cesarean section. Exclusion criteria includes unwillingness of the patient to continue participating in the study, height less than 150 cm, mental Disorders, corticosteroid use, alcohol consumption and drug abuse, contraindication to receive regional anesthesia, allergy to drugs used in the study, diabetes, hypertension and receiving antiemetic medications 24 hours prior to surgery

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Nausea and vomiting. Timepoint: Recovery and then at 1, 6, 12 and 24 hours after discharge from recovery. Method of measurement: VAS.;Itching. Timepoint: Recovery and then at 1, 6, 12 and 24 hours after discharge from recovery. Method of measurement: VAS.;Pain. Timepoint: Recovery and then at 1, 6, 12 and 24 hours after discharge from recovery. Method of measurement: VAS.	—

Secondary

Measure	Time frame
Patient Satisfaction. Timepoint: After discharge from recovery. Method of measurement: Visual analog scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKhadijeh Ghavibonyeh

Mazandaran University of Medical Science

ghavibonyehk@yahoo.com+98 11 3335 5080

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026